People exposed to secondhand cigarette smoke during adolescence may be more likely to develop multiple sclerosis (MS) later in…
Articles by Marisa Wexler, MS
New or worsening headaches are a more common side effect of interferon-beta (IFN-beta) treatment in people with multiple sclerosis (MS)…
Physical exercise can ease fatigue in people with multiple sclerosis (MS) and potentially benefit them in many other ways,…
Truxima, a biosimilar of rituximab, is comparable to the originator therapy in terms of effectiveness and safety for treating …
EHP-101, a cannabidiol-derived investigational therapy being developed by Emerald Health Pharmaceuticals (EHP) to treat multiple sclerosis (MS), is not a…
Janssen has submitted an application to the U.S. Food and Drug Administration (FDA) asking for…
Ponesimod may soon be a new oral therapy for people with relapsing multiple sclerosis (MS) in Europe, and a…
Janssen has submitted an application to the European Medicines Agency (EMA) asking that ponesimod be approved as…
AB Science‘s masitinib significantly slowed disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active…
New data from Public Health England (PHE) and the U.K. MS Society show that the number of people…
Progressive cognitive decline in patients with multiple sclerosis (MS) may not be as inevitable as previously thought, a study…
The agency in charge of health and social services for Quebec, known as the Institut national d’excellence en santé et…
The experimental BTK inhibitor SAR442168 showed an acceptable safety profile and met its primary endpoint — a significant…
The Multiple Sclerosis Association of America (MSAA) is celebrating 50 years of work and dedication to improving the lives…
Caring for children with multiple sclerosis (MS) can affect the mental health of their mothers over the long term,…
The National Institute for Health Care and Excellence (NICE) in the U.K. issued its final decision, approving the inclusion…
Genetic variations that increase body mass index (BMI) in childhood are associated with a higher risk of multiple sclerosis (MS)…
People with multiple sclerosis (MS) who complete training through a method called the modified Story Memory Technique (mSMT)…
Ocrevus (ocrelizumab) has been approved in Scotland as a treatment for early, inflammatory primary progressive multiple sclerosis (PPMS).
The first participant has been dosed in the Phase 2 REPAIR-MS clinical trial examining the effects of CNM-Au8, Clene…
Anavex Life Sciences has received a U.S. patent covering the use of Anavex 2-73 (blarcamesine) for the treatment of…
Gabapentinoids — a class of therapies sometimes used off-label to help control pain in people with multiple sclerosis (MS)…
Measuring the speed of signals sent to the brain by nerves in the eye could help assess if remyelination is…
A grant awarded recently by the National Institutes of Health (NIH) will fund research to explore how brain changes…
Small changes in daily activities, like sitting less and walking more, may be healthful for people with multiple sclerosis…
MetP Pharma‘s patent application for a new method to treat demyelinating and neuroinflammatory diseases, including multiple sclerosis (MS),…
Atlas Biotechnologies will fund and provide support to three research projects at the University of Alberta to possibly identify cannabis…
Prices for new multiple sclerosis (MS) therapies in the United States are decided most by competitors’ prices, and continual increases in…
There is a sizable gap between advancements in treatment for multiple sclerosis (MS)Â and their regulatory approval, which is a…
People with multiple sclerosis (MS) tend to have low levels in their blood serum of certain antibodies that can…